An update of “Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model”

BMC Infectious Diseases

Technical Advance

Mark H Rozenbaum¹  Pieter T de Boer¹  Albert C Noort¹  Hong Anh T Tu¹  Maarten J Postma¹ 

[1] Institute of Health Policy, Management and Evaluation, University of Toronto, Ontario, Canada;

关键词: Cost-effectiveness analysis;    Rotavirus vaccination;    the Netherlands;   

DOI  :  10.1186/1471-2334-13-54

 received in 2012-07-23, accepted in 2013-01-17,  发布年份 2013

来源: Springer

【 摘 要 】

BackgroundTo update a cost-effectiveness analysis of rotavirus vaccination in the Netherlands previously published in 2011.MethodsThe rotavirus burden of disease and the indirect protection of older children and young adults (herd protection) were updated.ResultsWhen updated data was used, routine infant rotavirus vaccination in the Netherlands would potentially become an even more cost-effective strategy than previously estimated with the incremental cost per QALY at only €3,000-4,000. Break-even total vaccination costs were indicated at €92–122, depending on the applied threshold.ConclusionsWe concluded that the results on potentially favourable cost-effectiveness in the previous study remained valid, however, the new data suggested that previous results might represent an underestimation of the economic attractiveness of rotavirus vaccination.

【 授权许可】

CC BY   
© Tu et al.; licensee BioMed Central Ltd. 2013